Metastatic breast cancer is the leading cause of breast cancer-related deaths. Predictive signatures for poor prognosis breast cancer are available and routinely employed in the clinical setting; however, these signatures describe the risk of metastasis, not the underlying biologic drivers of metastasis. Moreover, accompanying therapeutic approaches to prevent metastasis are not provided by these established signatures. The underlying biology driving metastasis is largely unknown. Identifying genetic drivers of metastatic breast cancer and the timing during which these changes occur is critical to the development of effective therapeutics to prevent and treat metastases; such a study has yet to be performed in human tissues. We hypothesize that specific genetic and/or genomic factors are specifically enriched in breast cancer metastasis, and that some metastatic features are established within primary tumors. Utilizing a Rapid Autopsy Protocol established at UNC Chapel Hill, we have collected 169 metastatic breast cancer tissues from 34 individuals and performed RNA and DNA whole exome sequencing.
Aim 1 will define those genetic features enriched in metastases through a statistical comparison of DNA copy number, point mutations, and RNA gene expression changes in metastatic breast cancer tissues as compared to 1000 primary breast cancers previously published through the Cancer Genome Atlas.
Aim 1 C will then compare DNA copy number alterations and point mutations for each individual patient's collection of metastases to establish a map of the acquisition of molecular changes across time. Patients with breast cancer brain metastases have extremely limited survival and no approved systemic therapies. Current literature from in vivo modeling suggests that significant changes to both breast cancer cells and the tumor microenvironment are critical for metastatic seeding and growth.
Aim 2 will establish specific genetic features of breast cancer brain metastasis and the altered signaling in the supporting adjacent brain parenchyma. Comparing gene expression in adjacent non-malignant brain parenchyma to matched distant brain parenchyma both in human tissues and in two in vivo breast cancer brain metastasis models will identify supporting microenvironment signals unique to the adjacent brain parenchyma. Our goal is to identify genetic features enriched in breast cancer metastasis, ultimately to define future therapeutic targets and help decrease mortality from breast cancer. Along with the superb environment at UNC Chapel Hill, exceptional mentoring by Dr. Perou and Dr. Anders, and a comprehensive training plan, this fellowship will provide a critical foundation to build my future career as an independently funded physician-scientist in the field of cancer metastases.

Public Health Relevance

Breast cancer spreading beyond the breast (metastasis) is the second leading cause of cancer-related death in women in the United States and the cause of breast cancer related death. An understanding of the underlying biology driving metastasis is desperately needed to identify therapeutic targets both to prevent metastasis and treat existing metastasis. This project will define potential genetic drivers of metastases in a human autopsy dataset of breast cancer metastases, and the results of this work will establish novel therapeutic targets ultimately to improve the treatment of metastatic breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
5F30CA200345-02
Application #
9206097
Study Section
Special Emphasis Panel (ZRG1-F09A-D (20)L)
Program Officer
Damico, Mark W
Project Start
2015-08-01
Project End
2019-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
2
Fiscal Year
2016
Total Cost
$41,551
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Genetics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Byrd, Rachel Chikowski; Mournighan, Kimberly J; Baca-Atlas, Michael et al. (2018) Generalized bullous fixed-drug eruption secondary to the influenza vaccine. JAAD Case Rep 4:953-955
Connolly, Nina P; Shetty, Amol C; Stokum, Jesse A et al. (2018) Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma. Sci Rep 8:1180
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Hoadley, Katherine A; Siegel, Marni B; Kanchi, Krishna L et al. (2017) Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. PLoS Med 14:e1002222
Kodack, David P; Askoxylakis, Vasileios; Ferraro, Gino B et al. (2017) The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci Transl Med 9:
Siegel, Marni B (2017) The Difficult Transition. JAMA Oncol 3:1626-1627
Van Swearingen, Amanda E D; Sambade, Maria J; Siegel, Marni B et al. (2017) Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro Oncol 19:1481-1493
Vitucci, Mark; Irvin, David M; McNeill, Robert S et al. (2017) Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma. Neuro Oncol 19:1237-1247
Silva, Grace O; Siegel, Marni B; Mose, Lisle E et al. (2017) SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling. Genome Biol 18:66
McNeill, Robert S; Canoutas, Demitra A; Stuhlmiller, Timothy J et al. (2017) Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro Oncol 19:1469-1480

Showing the most recent 10 out of 12 publications